Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05JFA
|
|||
| Former ID |
DIB006747
|
|||
| Drug Name |
INTERCEPT
|
|||
| Indication | Blood transfusion [ICD-11: QB98; ICD-10: Z51.3] | Phase 3 | [1] | |
| Infectious disease [ICD-11: 1A00-CA43.1; ICD-9: 001-139] | Phase 2 | [2] | ||
| Company |
Cerus
|
|||
| Structure |
 |
Download2D MOL |
||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Cerus. | |||
| REF 2 | ClinicalTrials.gov (NCT02310412) A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.